Biotechnology

Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)

HONG KONG, June 18, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®#  (tenofovir alafenamide 25 mg, TAF) from tenofovir disoproxil fumarate (T...

2021-06-18 10:00 2580

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

SINGAPORE, June 18, 2021 /PRNewswire/ -- Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed$24 million Series A financing round. The round was co-led by EVX Ventures andBoehringer Ingelheim Venture Fun...

2021-06-18 09:58 10772

Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board

SHANGHAI, June 17, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition ofJacques Mizrahi, Ph.D., to its scientific advisory board.

2021-06-17 19:49 3297

Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist

SHANGHAI, June 16, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces positive topline results of safety and pharmacodynamic ...

2021-06-16 21:00 4100

Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer's Disease

Following recent FDA approval of Biogen's Alzheimer antibody drug ADUHELM (TM), targeting oligomers of amyloid beta, Galimedix aims for first patients with its GAL-201 oral small molecule drug within one year. KENSINGTON, Md., June 16, 2021 /PRNewswire/ -- Galimedix, Inc., a clinical-stage bioph...

2021-06-16 04:38 1335

Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

BOSTON, June 15, 2021 /PRNewswire/ -- QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of the Eur...

2021-06-15 18:00 3097

Hummingbird Bioscience to Speak at 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"

HOUSTON and SINGAPORE, June 14, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that its Chief Scientific Officer and co-founder, DrJerome Boyd-Kirkup, will be speakin...

2021-06-15 13:04 1708

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-06-15 12:00 5322

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 15, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...

2021-06-15 09:06 2440

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

* 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest * 91% efficacy in high-risk populations * 100% efficacy against variants "not considered Variants of Concern/Interest" * All COVID-19 hospitalizations/death occurred in the placebo group * Company...

2021-06-15 07:06 6392

BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

VANCOUVER, British Columbia, June 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has d...

2021-06-15 04:19 16193

GENinCode Announces Major US Commercialisation Partnership With EVERSANA

OXFORD, England, June 15, 2021 /PRNewswire/ -- GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC ("EVERSANA") as its launch and commercialisation partner t...

2021-06-15 03:14 1622

Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of Foot and Mouth Disease Virus in Bovine, Swine and Ovine

The Tetracore® Real-Time PCR Test was validated for use on epithelial and serum samples ROCKVILLE, Md., June 12, 2021 /PRNewswire/ -- Tetracore announced today the licensing of their VetAlert™ Foot and Mouth Disease Virus (FMDV) RNA Diagnostic Test Kit by the United States Department of Agricult...

2021-06-12 06:27 7080

Less Salty, More Savory: Angel Yeast Reduces Global Sodium Intake with Yeast Extract Range

SHANGHAI, June 11, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast"), a listed high-tech yeast company inChina, made a splash at the 24th Food Ingredients China, one of the largest trade shows in the field of food additives and ingredients. 

2021-06-11 21:38 4879

Enamine implements CDD Vault to digitalize its integrated medicinal chemistry, ADME-PK and screening services

The company's expansion in the biological assay space aided by the data platform SAN FRANCISCO and KYIV, Ukraine, June 10, 2021 /PRNewswire/ -- Enamine, a leading provider of R&D Services as well asScreening Compounds, Fragments, Building Blocks and specialized libraries for Drug Discovery, annou...

2021-06-10 13:57 2278

CHEMriya - Billions of Molecules for R&D: OTAVA and BioSolveIT Team Up

11 Billion Novel Molecules: CHEMriya - OTAVA's On-Demand Chemical Space VAUGHAN, Ontario and SANKT AUGUSTIN, Germany, June 9, 2021 /PRNewswire/ -- Today, Canadian-based compound specialist OTAVA (aka OTAVAchemicals) and German frontrunner cheminformatics firm BioSolveIT announce the release of a ...

2021-06-09 21:00 2015

Hummingbird Bioscience and Novogene enter into strategic partnership to expand precision medicine testing for individuals with NRG1-fusion driven cancers in China

HOUSTON and SINGAPORE, June 9, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a strategic partnership with Asian genomic sequencing and bioinformatics company, Novoge...

2021-06-09 17:00 2091

Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer

SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd. incorporated inSingapore on 7th April 2017, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment of Charles S....

2021-06-09 13:38 2303

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 9, 2021 /PRNewswire/ -- Antengene's Partner, Karyopharm Therapeutics In...

2021-06-09 08:00 4003

Innoforce Pharmaceuticals to Participate in BIO International Digital Convention

HANGZHOU, China and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("Innoforce"), an innovation and partnership-focused biopharmaceutical company, today announces that the company is participating in the BIO International Digital Convention (BIO Digital) being held fromJun...

2021-06-08 19:00 2844